Arch Venture Corp purchased a new position in shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 965,660 shares of the biotechnology company’s stock, valued at approximately $631,000. Bellerophon Therapeutics accounts for about 0.6% of Arch Venture Corp’s portfolio, making the stock its 5th largest holding.
Separately, Vanguard Group Inc raised its holdings in Bellerophon Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after buying an additional 25,300 shares during the period. Hedge funds and other institutional investors own 54.68% of the company’s stock.
Several brokerages recently issued reports on BLPH. Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Maxim Group set a $3.00 price objective on shares of Bellerophon Therapeutics and gave the company a “buy” rating in a report on Monday, April 8th.
Shares of BLPH opened at $0.63 on Friday. The stock has a market capitalization of $43.42 million, a P/E ratio of -1.85 and a beta of -0.02. Bellerophon Therapeutics Inc has a 12-month low of $0.47 and a 12-month high of $3.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.99 and a current ratio of 2.99.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.11. Analysts expect that Bellerophon Therapeutics Inc will post -0.21 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Riverton Roll and is the property of of Riverton Roll. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://rivertonroll.com/news/2019/06/14/arch-venture-corp-purchases-new-holdings-in-bellerophon-therapeutics-inc-nasdaqblph.html.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Read More: How does a security become overbought?
Want to see what other hedge funds are holding BLPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellerophon Therapeutics Inc (NASDAQ:BLPH).
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.